IlluminOss Receives 510K Clearance for a New Light Console for its Implants that Provide Strength for Fragile and Geriatric Bone
By combining years of clinical experience with cutting-edge research and development, IlluminOss Medical announces it has received FDA 510(k) clearance for a new Light-Emitting Diode (LED) Console to speed curing of its patented, light-cured implants. IlluminOss is the first and only…
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a non-profit organization dedicated to finding a cure for Parkinson’s disease (PD), today…
Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead asset MTX652, allowing Mission to…
State-of-the-Art Simran Sound Centre Opens in Ludhiana, Elevating Hearing Care Standards to New Heights
In a significant step towards enhancing hearing care in India, Widex India proudly unveils its latest venture – the Simran Sound Centre, in Ludhiana, Punjab. This state-of-the-art clinic was inaugurated by Mr. Avinash Pawar, CEO of WS Audiology India, alongside…
Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments
Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED, a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial…
Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it
This is a major milestone for Human Biome, the field of microbiome medicine and whole epidemiology. Antibiotic resistance is a growing threat to public health, and new treatments are urgently needed. The New-Generation Biotherapeutic (NGB) drug candidate has the potential to…
Telehealth resources for eating disorders practitioners increases
The International Association of Eating Disorders Professionals (iaedp™) is supporting telehealth practitioners and professionals in the eating disorder field. Telehealth saw a boom during the pandemic; the concept and practice were already in place well but is now a common occurrence. Rapidly,…
Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical’s New AI Software
Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™). Built with leading clinicians and UK NHS hospitals, the CE mark means the software can…
Studying Immune Cell Aging in Space May Lead to New Therapies for Patients on Earth
A healthy immune system is what defends the body from invaders like bacteria and viruses. But for the elderly and those facing chronic diseases, the immune system can wear down over time. To better understand the relationship between immune aging…
‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan
BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to…
